Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Download the full guide to explore: The rise of GLP-1 medications Employer healthcare cost considerations Wellness program implications Long-term behavior change strategies The role of wellness technology Future workplace wellness trends
A small 2024 study found no semaglutide in breast milk samples, and a 2026 study found little to no tirzepatide
No information on co-medication was available for the POSH cohort, a reason why we cannot comment on their possible influence on the results
Risks and Side Effects While semaglutide is generally well-tolerated, it is important to be aware of potential side effects and risks: Common Side Effects Nausea and Vomiting : These are the most commonly reported side effects, particularly when starting treatment
Pharmacological Treatment of Obesity in Older Adults
Here, we used the US Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated GLP-1RA ( n = 215,970) and compared them to those who initiated sulfonylureas ( n = 159,465), dipeptidyl peptidase 4 (DPP4) inhibitors ( n = 117,989) or sodiumglucose cotransporter-2 (SGLT2) inhibitors ( n = 258,614), a control group composed of an equal proportion of individuals initiating sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors ( n = 536,068), and a control group of 1,203,097 individuals who continued use of non-GLP-1RA antihyperglycemics (usual care)
